112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders

HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.

Key Highlights:

   -- Sepsis & NETosis Validation: Peer-reviewed paper and independent 
      Editorial published demonstrating that Nu.Q$(R)$ NETs is an independent 
      predictor of 28-day mortality and the need for renal (kidney) replacement 
      therapy (RRT) in sepsis and septic shock patients. $7.3 
      million government-backed DETECSEPS program in France due to start 
      recruitment in September 2026. 
 
   -- Demonstrates Clinical Utility of Breakthrough Finger-Prick Detection of 
      Nucleosomes: Expanding global market potential for sepsis testing using 
      lateral flow, thereby potentially greatly expanding the addressable 
      market and utility. 
 
   -- European Lung Cancer Reimbursement: Plans formal conditional 
      reimbursement submission in France by the end of 2026 to enable routine 
      clinical use. 
 
   -- First Half Revenue Growth: Reported $1.4M of revenue in the first half of 
      2026, representing a 112% increase year-over-year. 
 
   -- Feline Lymphoma Manuscript Submission: Submitted for publication the 
      clinical manuscript for the Nu.Q(R) Vet cancer test in cats; $5 million 
      milestone payment anticipated subsequent to publication. 
 
   -- Global Licensing Momentum: Confirms active discussions with more than a 
      dozen of the world's leading diagnostic and liquid biopsy companies, 
      including for technical evaluations. 
 
   -- Newly Announced Collaboration: successfully transferred Volition 
      Nu.Q(R) NETs assay onto Sysmex Corporation's platform, in preparation for 
      anticipated broader agreement. Sysmex Corporation is a multi-billion 
      dollar market capitalization company listed on the Tokyo Stock Exchange. 
 
   -- Capture-Seq$(TM)$ Platform: Peer-reviewed paper published: validation 
      cohort detected over 95% of Stage I and II cancers, Underscores a $23 
      billion annualized opportunity in cancer detection. 

Sepsis & NETosis Validation

We were honored that Nu.Q(R) NETs H3.1 featured in an editorial(1) in Critical Care Medicine, a prominent journal for Critical Care doctors around the world and were excited that the findings of another large-scale independent clinical study were peer-reviewed and published(2) in that journal. These findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market(3) .

The inclusion of our Nu.Q(R) NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed ($7.3 million) program in France remains on track to start in the third quarter of 2026. The DETECSEPS program provides an opportunity to receive individualized or personalized care, adjusted to the risk of deterioration and progression to sepsis.

In the first half of 2026, we also reported two new, potentially large, clinical use cases for our Nu.Q(R) NETs assay beyond sepsis. In conjunction with the Mayo Clinic(4) , we demonstrated Nu.Q(R) NETs' potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care(4) . We plan to further validate with Mayo the use of Nu.Q(R) NETs in trauma patients.

We have also demonstrated the potential use of Nu.Q(R) NETs for patient management of a chronic disease, Hidradenitis Suppurativa(5) , which affects about 1% of the world's population(6) .

NETosis-related diseases beyond sepsis provide an additional $1 billion Total Addressable Market on an annualized basis(3) .

Breakthrough Finger-Prick Detection of Nucleosomes

Excitingly for Nu.Q(R) NETs we have also made excellent progress in the development and evaluation of our lateral flow prototype assay. This has the potential to strengthen our product portfolio. In April, we reported the technical breakthrough of being able to detect nucleosomes in capillary blood (or finger prick blood) and more recently in August, we reported we have demonstrated correlation of the lateral flow prototype assay and our established CE marked automated Nu.Q(R) NETs assay in samples of critically ill, confirmed sepsis patients in the Intensive Care Unit.

The ability to rapidly identify high-risk patients at the Point-of-Care by quantifying their nucleosome levels using a finger-prick sample and simple lateral flow device aims to enable quicker clinical decision making and consequently better patient outcomes.

This finger prick sample test could be used at the bedside, in the ER, or even at home in a self-test lateral flow kit, similar to COVID-19 or pregnancy testing, thereby greatly expanding the potential market beyond centralized lab testing.

With recent estimates indicating approximately 166 million cases of sepsis worldwide, the addressable market is huge. All-cause sepsis related deaths in 2021 represented 31.5%(7) of total global deaths, with the highest burden of mortality in lower-middle-income countries.

We are now actively targeting NGO partnerships and strategic collaborations with companies operating in low income countries to accelerate the commercialization and market penetration of our breakthrough Lateral Flow Assay.

Nu.Q(R) Lung Cancer Reimbursement Submission

Lung Cancer remains the major cause of cancer-related mortality worldwide.

We believe that Nu.Q(R) Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring.

Research conducted by our long-term collaborators in Taiwan and Lyon demonstrates that our Nu.Q(R) Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey(8-13) .

This evidence provides the basis of our European lung cancer reimbursement submission supported by our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers.

Reimbursement is the next step on the path to the first use of Nu.Q(R) in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives. This quarter we participated in our first pre-submission meeting with the authorities and anticipate a follow-up meeting and ultimately a submission in 2026.

Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q(R) in the human cancer field and, assuming achievement, we anticipate the introduction into routine clinical use in France and will then set our sights on rolling-out to other countries.

Capture-Seq(TM) Breakthrough in Cancer Detection.

We were delighted thar our manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy" has been peer-reviewed and published(14) . This, our first peer-reviewed paper for Capture-Seq(TM), showcasing both a new method and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers.

We also announced over 95% sensitivity for stage I & II cancers with 95% specificity in a blinded validation cohort(15) . For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq(TM) could contribute to Multi-Cancer Early Detection (MCED) fulfilling a significant unmet clinical need.

We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development of our Capture-Seq(TM) technology and undertake technical evaluations with potential licensors. We believe that this technology could, with further development, become very widely used and are actively advancing structured discussions with potential commercial partners to accelerate the integration and launch of this technology as soon as possible.

We believe MCED represents a significant commercial opportunity with Total Addressable Markets on an annualized basis of approximately $23 billion and a potential additional $13 billion should it also prove useful in the detection of Minimal Residual Disease(3) .

Companion Animal Health: Nu.Q(R) Vet Feline Milestone

We announced the submission of a clinical manuscript reporting the high accuracy of our Nu.Q(R) Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species(17) . At 97% specificity the assay detected 86% of feline lymphomas(16) . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.

This represents a tremendous commercial opportunity for Volition:

   -- the publication of this study in a peer reviewed journal is expected 
      subsequently to unlock a $5 million contractual milestone payment. 
 
   -- we will also generate ongoing revenue in this large and growing market 
      where our technology meets an unmet need. 

The Nu.Q(R) Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space(3) .

Our Goal and Vision